Enveric Biosciences (NASDAQ:ENVB) and VBI Vaccines (NASDAQ:VBIV) Critical Contrast

Enveric Biosciences (NASDAQ:ENVB) and VBI Vaccines (NASDAQ:VBIV) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, risk and analyst recommendations.

Valuation and Earnings

This table compares Enveric Biosciences and VBI Vaccines’ top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enveric Biosciences	N/A	N/A	-$17.29 million	($8.11)	-0.11
VBI Vaccines	$8.68 million	1.99	-$92.84 million	($11.68)	-0.05

Enveric Biosciences has higher earnings, but lower revenue than VBI Vaccines. Enveric Biosciences is trading at a lower price-to-earnings ratio than VBI Vaccines, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Enveric Biosciences has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500. Comparatively, VBI Vaccines has a beta of 1.9, indicating that its stock price is 90% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Enveric Biosciences and VBI Vaccines, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enveric Biosciences	0	0	1	0	3.00
VBI Vaccines	0	0	0	0	N/A

Enveric Biosciences currently has a consensus price target of $10.00, suggesting a potential upside of 1,023.60%. Given Enveric Biosciences’ higher possible upside, research analysts plainly believe Enveric Biosciences is more favorable than VBI Vaccines.

Insider & Institutional Ownership

13.8% of Enveric Biosciences shares are owned by institutional investors. Comparatively, 12.3% of VBI Vaccines shares are owned by institutional investors. 1.2% of Enveric Biosciences shares are owned by company insiders. Comparatively, 10.4% of VBI Vaccines shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Enveric Biosciences and VBI Vaccines’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Enveric Biosciences	N/A	-349.01%	-187.74%
VBI Vaccines	-1,069.29%	-234.77%	-47.11%

About Enveric Biosciences

Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

About VBI Vaccines

VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.